Mr. Allen Davidoff reports

XORTX MEETS NASDAQ CONTINUED LISTING REQUIREMENTS

XORTX Therapeutics Inc. has received a letter of compliance from the Nasdaq Stock Market LLC's listing qualifications department in connection with Nasdaq Rule 5550(a)(2) that requires a listed company's shares to maintain a minimum bid price of $1 (U.S.) per share. To regain compliance, the company's common shares were required to trade at or above $1 (U.S.) per share for at least 10 consecutive trading days. Following implementation of a one-for-five reverse split of the company's common shares on April 6, 2026, this requirement was met on April 17, 2026, and the company received the compliance letter from Nasdaq April 20, 2026. As a result, the deficiency in the minimum bid requirement has been cured.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: (1) its lead program XRx-026 program for the treatment of gout; (2) XRx-008 program for ADPKD; and (3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the company is developing XRx-225, a preclinical-stage program for Type 2 diabetic nephropathy and recently acquired VB4-P5 program, which is currently at the preinvestigational-new-drug stage of development and targets both rare and prevalent forms of kidney disease. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, it is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

We seek Safe Harbor.